University of California San Francisco

Kevin M. Shannon, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
shannon_kevin

Professor, Department of Pediatrics, UCSF
Roma and Marvin Auerback Distinguished Professorship in Pediatric Molecular Oncology, UCSF

Phone: (415) 476-7932 (voice)
Box 3112, UCSF
San Francisco, CA 94143-3112

View on UCSF Profiles


Additional Websites


Education

Williams College, Williamstown, MA, A.B., 1976, Biology, Liberal Arts
Cornell University, New York, NY, M.D., 1979, Medicine
University of Texas Southwestern, Dallas, TX, Resident, 1982, Pediatrics
University of California, San Francisco (UCSF), Postdoctoral, 1988, Hematology/Oncology


Professional Experience

  • 1982-85
    Attending Pediatrician, Naval Hospital, Oakland, CA
  • 1985-88
    Fellow in Pediatric Hematology/Oncology and Instructor in Pediatrics, UCSF
  • 1988-92
    Attending Pediatric Hematologist/Oncologist, Naval Hospital, Oakland, CA
  • 1992-94
    Assistant Professor of Pediatrics and Attending Pediatric Hematologist/Oncologist, UCSF
  • 1989-93
    Hematopoietic Growth Factors Subcommittee, American Society of Hematology
  • 1990-present
    Acute Myelogenous Leukemia Strategy Group Children's Cancer Study Group (Co-Chair 1997-99)
  • 1988-93
    Cancer Biology Committee, Children's Cancer Study Group (Chair 1991-94)
  • 1991-92
    Pediatric Residency Program Director, Naval Hospital, Oakland, CA
  • 1994-98
    Associate Professor of Pediatrics, UCSF
  • 1997-present
    Leader, Program in Hematopoietic Malignancies, UCSF Cancer Center
  • 1997-present
    Professor of Pediatrics, UCSF
  • 2005
    Vice Chair for Research, Department of Pediatrics, UCSF
  • 2006
    Director, UCSF Medical Scientist Training Program

Honors & Awards

  • 1985 and 1989
    Outstanding Teacher, Pediatrics Department, Naval Hospital, Oakland
  • 1985 and 1993
    Navy Commendation Medals
  • 1986
    Outstanding Fellow's Teaching Award, Pediatrics Department, UCSF
  • 1988
    David W. Smith Research Award, Western Society for Pediatric Research
  • 1988 and 1989
    Navy Achievement Medals
  • 1992
    Winner, Navy Academic Medicine Research Competition
  • 1993
    Nycomed Research Award of the International Society for Pediatric Oncology (SIOP)
  • 1994
    Ross Outstanding Young Investigator Award, Western Society for Pediatric Research
  • 1998
    American Academy of Pediatrics Award for Excellence in Pediatric Research
  • 2000
    Roma and Marvin Auerback Distinguished Professor of Pediatric Molecular Oncology, UCSF
  • 2004
    Samuel Rosenthal Prize for Excellence in Academic Pediatrics
  • 2006
    National Cancer Institute MERIT Award

Selected Publications

  1. Dail M, Wong J, Lawrence J, O'Connor D, Nakitandwe J, Chen SC, Xu J, Lee LB, Akagi K, Li Q, Aster JC, Pear WS, Downing JR, Sampath D, Shannon K. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature. 2014 Sep 25; 513(7519):512-6.
    View on PubMed
  2. Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW. MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia. Cancer Cell. 2014 May 12; 25(5):652-65.
    View on PubMed
  3. Stieglitz E, Liu YL, Emanuel PD, Castleberry RP, Cooper TM, Shannon KM, Loh ML. Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. Blood. 2014 Feb 27; 123(9):1426-7.
    View on PubMed
  4. North M, Shuga J, Fromowitz M, Loguinov A, Shannon K, Zhang L, Smith MT, Vulpe CD. Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke. BMC Cancer. 2014; 14(1):6.
    View on PubMed
  5. Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K. PLC-? and PI3K Link Cytokines to ERK Activation in Hematopoietic Cells with Normal and Oncogenic Kras. Sci Signal. 2013; 6(304):ra105.
    View on PubMed
  6. Li Q, Bohin N, Wen T, Ng V, Magee J, Chen SC, Shannon K, Morrison SJ. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature. 2013 Dec 5; 504(7478):143-7.
    View on PubMed
  7. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
    View on PubMed
  8. Lu J, Zavorotinskaya T, Dai Y, Niu XH, Castillo J, Sim J, Yu J, Wang Y, Langowski JL, Holash J, Shannon K, Garcia PD. Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood. 2013 Aug 29; 122(9):1610-20.
    View on PubMed
  9. Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov. 2013 Sep; 3(9):993-1001.
    View on PubMed
  10. Shieh A, Ward AF, Donlan KL, Harding-Theobald ER, Xu J, Mullighan CG, Zhang C, Chen SC, Su X, Downing JR, Bollag GE, Shannon KM. Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo. Blood. 2013 Jun 13; 121(24):4884-93.
    View on PubMed
  11. Hartzell C, Ksionda O, Lemmens E, Coakley K, Yang M, Dail M, Harvey RC, Govern C, Bakker J, Lenstra TL, Ammon K, Boeter A, Winter SS, Loh M, Shannon K, Chakraborty AK, Wabl M, Roose JP. Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis. Sci Signal. 2013 Mar 26; 6(268):ra21.
    View on PubMed
  12. Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013 Jan 2; 123(1):335-9.
    View on PubMed
  13. Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012 Oct 25; 120(17):3397-406.
    View on PubMed
  14. Shah NP, Shannon K. Advancing the STATus of MPN pathogenesis. Blood. 2012 Apr 12; 119(15):3374-6.
    View on PubMed
  15. Xu J, Hedberg C, Dekker FJ, Li Q, Haigis KM, Hwang E, Waldmann H, Shannon K. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood. 2012 Jan 26; 119(4):1032-5.
    View on PubMed
  16. Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med. 2011 Mar 30; 3(76):76ra27.
    View on PubMed
  17. Shannon K, Li Q. Oncogenic Ras scales the ALPS. Blood. 2011 Mar 10; 117(10):2747-8.
    View on PubMed
  18. Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M, Sharma T, Gavin J, Kutok JL, Iscove NN, Shannon KM, Dick JE, Neel BG, Braun BS. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood. 2011 Apr 21; 117(16):4253-61.
    View on PubMed
  19. Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper RO, Shannon K. Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer Res. 2011 Jan 1; 71(1):106-15.
    View on PubMed
  20. Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood. 2011 Feb 10; 117(6):2022-32.
    View on PubMed

Go to UCSF Profiles, powered by CTSI